Nxera Pharma Co., Ltd. (SOLTF)
| Market Cap | 731.62M +19.0% |
| Revenue (ttm) | 205.67M +7.1% |
| Net Income | -48.00M |
| EPS | -0.53 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300 |
| Open | 7.86 |
| Previous Close | 8.35 |
| Day's Range | 7.64 - 8.35 |
| 52-Week Range | 4.90 - 8.35 |
| Beta | 0.25 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 30, 2026 |
About Nxera Pharma
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychi... [Read more]
Financial Performance
In 2025, Nxera Pharma's revenue was 29.62 billion, an increase of 2.71% compared to the previous year's 28.84 billion. Losses were -12.53 billion, 159.0% more than in 2024.
Financial numbers in JPY Financial StatementsNews
Nxera Pharma Earnings Call Transcript: Q2 2026
Revenue rose 25% year-over-year to JPY 18.9 billion, with a return to profitability and strong growth in both commercial and platform segments. Key products and partnerships drove milestone achievements, while the company targets further expansion, new partnerships, and AI-driven drug discovery.
Nxera Pharma Quarterly report: Q2 2026
Nxera Pharma has published its Q2 2026 quarterly earnings report on August 7, 2026.
Nxera Pharma Slides: Q2 2026
Nxera Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 7, 2026.
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the developmen...
Nxera Pharma Transcript: Jefferies Global Healthcare Conference 2026
Significant progress was highlighted in obesity and rare disease pipelines, with novel oral small molecules advancing and key assets poised for out-licensing. Commercial growth in Japan, milestone income, and a new AI-driven drug discovery platform underpin a strategy focused on specialty and rare diseases.
Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
Tokyo, Japan and Cambridge, UK, 2 June 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan...
Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026
Tokyo, Japan and Cambridge, UK, 26 May 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat' at the Je...
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) entered into a license agreement with a newly established company (“N...
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) ...
Nxera Pharma Quarterly report: Q1 2026
Nxera Pharma has published its Q1 2026 quarterly earnings report on May 1, 2026.
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Tokyo, Japan and Cambridge and London, UK, 20 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a third R&D milestone under its multi-target discov...
Nxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Tokyo, Japan and Cambridge, UK, 14 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Holling Bio-Pharma Corp. (“Holling”), a leading pharmaceutical d...
Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
Tokyo, Japan and Cambridge, UK, 13 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a...
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Tokyo, Japan and Cambridge, UK, 09 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target ...
Nxera Pharma Slides: Corporate presentation
Nxera Pharma has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that...
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development mi...
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Tokyo, Japan and Cambridge, UK, 4 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the Ministry o...
Nxera Pharma Proposes Changes to its Board of Directors
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated be...
Nxera Pharma Earnings Call Transcript: Q4 2025
FY 2025 saw revenue growth to JPY 29.6B, led by strong product sales, but operating losses due to higher R&D and restructuring costs. FY 2026 targets include profitability, cost reduction, and continued commercial growth, with upside from milestone deals and new product launches.
Nxera Pharma Quarterly report: Q4 2025
Nxera Pharma has published its Q4 2025 quarterly earnings report on February 13, 2026.
Nxera Pharma Slides: Q4 2025
Nxera Pharma has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 13, 2026.
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the...
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone ass...
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has entered into a license agreement (the “Agreement”) with a newly esta...